First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

Clinical trial NCT02729298 · COMPLETED

Trial details

NCT number: NCT02729298
Sponsor: Sumitomo Pharma America, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumors EGFR Positive Non-small Cell Lung Cancer Colorectal Carcinoma Recurrent Ovarian Carcinoma BRAF-Mutated Melanoma

Start date: 2016-12-14
Primary completion: 2022-06-29
Enrollment: 177

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.